ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Abe DeAnda, Jr
Marc R. Moon
Conrad M. Vial
Masashi Komeda
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DeAnda, A.
Right arrow Articles by Miller, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeAnda, A., Jr
Right arrow Articles by Miller, D. C.

Ann Thorac Surg 1994;58:344-350
© 1994 The Society of Thoracic Surgeons


Articles

Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass

Abe DeAnda, Jr, MDa,b,*, Steven E. Coutre, MDa,b, Marc R. Moon, MDa,b,*, Conrad M. Vial, BAa,b, Linda C. Griffin, PhDa,b, Veronica S. Law, BAa,b, Masashi Komeda, MDa,b,*, Lawrence L.K. Leung, MDa,b, D.Craig Miller, MDa,b,*

a Department of Cardiovascular and Thoracic Surgery, Stanford University Schnol of Medicine, Stanford, California, USA
b Department of Cardiovascular and Thoracic Surgery, Gilead Sciences, Foster City, California USA

* Address reprint requests to Dr Miller, Department of Cardiovascular and Thoracic Surgery, Palk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA 94305-5247.

Heparin is normally used for anticoagulation during cardiopulmonary bypass (CPB), but its use is contraindicated in patients with a history of heparin-induced thrombocytopenia, heparin-provoked thrombosis, or both. Heparin therapy can also be ineffective due to heparin resistance. A short-acting, oligonucleotide-based thrombin inhibitor (thrombin aptamer) may potentially serve as a substitute for heparin in these and other clinical situations. We tested a novel thrombin aptamer in a canine CPB pilot study to determine its anticoagulant efficacy, the resultant changes in coagulation variables, and the aptamer's clearance mechanisms and pharmacokinetics. Seven dogs were studied initially: Four received varied doses of the aptamer (to establish the pharmacokinetic profile) and 3 received heparin. Subsequently, 4 other dogs underwent CPB, receiving a constant infusion of the aptamer before CPB (to characterize the baseline coagulation status), with partial CPB and hemodilution, during 60 minutes of total CPB, and, finally, after a 2-hour recovery period. At a 0.5 mg · kg–1 · min–1 dose, the activated clotting time rose with aptamer infusion from 106 ± 12 seconds to 187 ± 8 seconds (± 1 standard deviation) (p = 0.014), increased further with hemodilution (to 259 ± 41 seconds; p = 0.017), and was even more prolonged during total CPB (> 1,500 seconds; p < 0.001). This later increase in the activated clotting time paralleled a rise in the plasma concentration of the thrombin aptamer during total CPB, as determined by high-performance liquid chromatography. The calculated plasma aptamer elimination half-life increased from 1.9 minutes during baseline conditions to 7.7 minutes during total bypass, suggesting that the pulmonary vasculature plays a role in aptamer clearance. Importantly, the coagulation profile returned to normal levels within 5 minutes of halting aptamer infusion. There was no difference in platelet or fibrinogen consumption versus those of heparin. Postoperative bleeding (chest tube output) was minimal (95 to 150 mL over a 2-hour period), and serum chemistry profiles were normal. These preliminary pilot data indicate that this thrombin aptamer is both safe and, using conventional measures of anticoagulation, effective as an anticoagulant in this short-term canine CPB model, and that its pharmacokinetics are predictable. Furthermore, the pulmonary circulation appears to play a major role in the clearance of the aptamer.




This article has been cited by other articles:


Home page
RNAHome page
S. M. Nimjee, S. Oney, Z. Volovyk, K. M. Bompiani, S. B. Long, M. Hoffman, and B. A. Sullenger
Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin
RNA, December 1, 2009; 15(12): 2105 - 2111.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Kim, J. A. Phillips, H. Liu, H. Kang, and W. Tan
Using photons to manipulate enzyme inhibition by an azobenzene-modified nucleic acid probe
PNAS, April 21, 2009; 106(16): 6489 - 6494.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Kim, Z. Cao, and W. Tan
Molecular assembly for high-performance bivalent nucleic acid inhibitor
PNAS, April 15, 2008; 105(15): 5664 - 5669.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
K. Ikebukuro, Y. Okumura, K. Sumikura, and I. Karube
A novel method of screening thrombin-inhibiting DNA aptamers using an evolution-mimicking algorithm
Nucleic Acids Res., July 7, 2005; 33(12): e108 - e108.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. Andreotti and R. C. Becker
Atherothrombotic Disorders: New Insights From Hematology
Circulation, April 12, 2005; 111(14): 1855 - 1863.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. R. White, S. Shan, C. P. Rusconi, G. Shetty, M. W. Dewhirst, C. D. Kontos, and B. A. Sullenger
Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2
PNAS, April 29, 2003; 100(9): 5028 - 5033.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
F. Follis and C. A. Schmidt
Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis
Ann. Thorac. Surg., December 1, 2000; 70(6): 2173 - 2181.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. W. Frederiksen
Cardiopulmonary bypass in humans: bypassing unfractionated heparin
Ann. Thorac. Surg., October 1, 2000; 70(4): 1434 - 1443.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. J. Wilhelm, C. Schmid, D. Kececioglu, T. Mollhoff, H. Ostermann, and H. H. Scheld
Cardiopulmonary Bypass in Patients With Heparin-Induced Thrombocytopenia Using Org 10172
Ann. Thorac. Surg., March 1, 1996; 61(3): 920 - 924.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1994 by The Society of Thoracic Surgeons.